10403-51-7 Usage
Description
Mitindomide is an immunomodulatory drug that is being explored for its potential in treating autoimmune diseases, inflammatory conditions, and cancers. It functions by modulating the immune system and reducing inflammation, showing promise in preclinical studies and currently undergoing phase I/II clinical trials for multiple myeloma treatment.
Uses
Used in Pharmaceutical Industry:
Mitindomide is used as a therapeutic agent for the treatment of autoimmune diseases and inflammatory conditions due to its ability to modulate the immune system and reduce inflammation.
Used in Oncology:
Mitindomide is used as a potential treatment for cancers, particularly in phase I/II clinical trials for multiple myeloma, a type of blood cancer, due to its immunomodulatory and anti-inflammatory properties that may help combat cancerous conditions.
Further research and clinical trials are necessary to fully understand the safety and efficacy of Mitindomide in these applications.
Check Digit Verification of cas no
The CAS Registry Mumber 10403-51-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,4,0 and 3 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 10403-51:
(7*1)+(6*0)+(5*4)+(4*0)+(3*3)+(2*5)+(1*1)=47
47 % 10 = 7
So 10403-51-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H12N2O4/c17-11-7-3-1-2-4(8(7)12(18)15-11)6-5(3)9-10(6)14(20)16-13(9)19/h1-10H,(H,15,17,18)(H,16,19,20)
10403-51-7Relevant articles and documents
Synthesis of Congeners and Prodrugs of the Benzene Maleimide Photoadduct Mitindomide as Potential Antitumor Agents. 2
Deutsch, Howard M.,Gelbaum, Leslie T.,McLaughlin, Mark,Fleischmann, Thomas J.,Earnhart, Lawrence L.,et al.
, p. 2164 - 2170 (1986)
Potential prodrugs of the highly insoluble, diimide antitumor agent mitindomide (1b) were synthesized by several different methods.The condensation reaction between mitindomide and formaldehyde cleanly gave the stable bis(hydroxymethyl) compound 7a, which was partially soluble in water (ca. 0.8percent) and showed improved activity in the P-388 screen.When this compound was treated with secondary amines, good yields of Mannich bases could be isolated.The compound from N-methylpiperazine (7b) had excellent properties and is a candidate for clinical trials.Condensation with other aldehydes gave either no reaction or compounds with poor activity.A water-soluble ester was prepared from 7a and succinic anhydride, but had reduced potency and activity.Oxidation of the double bond of 1a with ozone gave an inactive diacid, whereas the dihydro compound was as active as the olefin.When other aromatics (anisole, p-xylene, mesitylene) were photolyzed with maleimide, the resulting photoproducts were found to be inactive.Diimides from other ring system were synthesized from the corresponding anhydrides and found to be inactive, However, the bis(hydroxymethyl) derivative of one of these (12a) was active in the P-388 screen.
